Imatinib mesylate has anti-inflammatory properties, because it is a specific and potent inhibitor of several protein tyrosine kinases. Paniagua et al. have investigated imatinib's mechanism of ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

"Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers" was originally created and published by Pharmaceutical ...

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

Inhibikase’s cardiopulmonary disease portfolio is led by IkT-001Pro, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension that will deliver imatinib in a form that the Company ...